Kura Oncology (NASDAQ: KURA) insider transactions
In the twelve months to 10 November 2026, executives and directors of Kura Oncology reported 40 open-market sales of 368,073 shares ($3.8m) and 2 open-market purchases of 200,000 shares ($2.4m), by 8 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 29 September 2026 | Powl Brian T. | Chief Commercial Officer | Open-market sale | −15,430 | $10.75 | 136,819 | Form 4 |
| 29 September 2026 | Leoni Mollie | Chief Medical Officer | Open-market sale | −28,802 | $10.75 | 141,095 | Form 4 |
| 29 September 2026 | Ford Kathleen | Chief Operating Officer | Open-market sale, 10b5-1 plan | −3,668 | $10.75 | 142,986 | Form 4 |
| 28 September 2026 | Powl Brian T. | Chief Commercial Officer | Open-market sale | −9,020 | $10.50 | 160,249 | Form 4 |
| 28 September 2026 | Powl Brian T. | Chief Commercial Officer | Open-market sale | −8,000 | $10.56 | 152,249 | Form 4 |
| 28 September 2026 | Doyle Thomas James | SVP, Finance & Accounting | Open-market sale | −4,607 | $10.50 | 142,428 | Form 4 |
| 28 September 2026 | Leoni Mollie | Chief Medical Officer | Open-market sale | −12,448 | $10.50 | 169,897 | Form 4 |
| 28 September 2026 | Ford Kathleen | Chief Operating Officer | Open-market sale, 10b5-1 plan | −6,906 | $10.50 | 146,654 | Form 4 |
| 28 September 2026 | Bair Teresa Brophy | Chief Legal Officer | Open-market sale, 10b5-1 plan | −8,442 | $10.50 | 187,002 | Form 4 |
| 24 September 2026 | Burrows Francis | Chief Scientific Officer | Option exercise | +30,000 | $6.15 | 63,053 | Form 4 |
| 24 September 2026 | Burrows Francis | Chief Scientific Officer | Open-market sale | −20,726 | $10.83 | 42,327 | Form 4 |
| 24 August 2026 | Wilson Troy Edward | President and CEO | Open-market purchase | +100,000 | $12.39 | 479,194 | Form 4 |
| 21 August 2026 | Powl Brian T. | Chief Commercial Officer | Open-market sale | −4,345 | $11.89 | 169,269 | Form 4 |
| 19 August 2026 | Bair Teresa Brophy | Chief Legal Officer | Open-market sale | −31,487 | $12.63 | 195,444 | Form 4 |
| 17 August 2026 | Wilson Troy Edward | President and CEO | Open-market purchase | +100,000 | $11.12 | 379,194 | Form 4 |
| 18 June 2026 | Leoni Mollie | Chief Medical Officer | Open-market sale | −84,929 | $9.82 | 182,345 | Form 4 |
| 21 May 2026 | Powl Brian T. | Chief Commercial Officer | Open-market sale | −10,000 | $11.00 | 173,614 | Form 4 |
| 19 May 2026 | Powl Brian T. | Chief Commercial Officer | Open-market sale | −339 | $9.21 | 183,614 | Form 4 |
| 19 May 2026 | Ford Kathleen | Chief Operating Officer | Open-market sale | −2,257 | $9.08 | 153,560 | Form 4 |
| 18 May 2026 | Bair Teresa Brophy | Chief Legal Officer | Open-market sale | −2,256 | $9.38 | 226,931 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Kura Oncology page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.